CN102014900B - 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用 - Google Patents

一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用 Download PDF

Info

Publication number
CN102014900B
CN102014900B CN200980115801.XA CN200980115801A CN102014900B CN 102014900 B CN102014900 B CN 102014900B CN 200980115801 A CN200980115801 A CN 200980115801A CN 102014900 B CN102014900 B CN 102014900B
Authority
CN
China
Prior art keywords
tumor
cancer
npy5r
pyrazolyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115801.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102014900A (zh
Inventor
潘国华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN102014900A publication Critical patent/CN102014900A/zh
Application granted granted Critical
Publication of CN102014900B publication Critical patent/CN102014900B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200980115801.XA 2008-03-11 2009-03-10 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用 Expired - Fee Related CN102014900B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6890008P 2008-03-11 2008-03-11
US61/068,900 2008-03-11
US12690908P 2008-05-08 2008-05-08
US61/126,909 2008-05-08
US19035608P 2008-08-28 2008-08-28
US61/190,356 2008-08-28
US11823108P 2008-11-26 2008-11-26
US61/118,231 2008-11-26
PCT/CA2009/000286 WO2009111868A1 (en) 2008-03-11 2009-03-10 Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist

Publications (2)

Publication Number Publication Date
CN102014900A CN102014900A (zh) 2011-04-13
CN102014900B true CN102014900B (zh) 2014-04-02

Family

ID=41064694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115801.XA Expired - Fee Related CN102014900B (zh) 2008-03-11 2009-03-10 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用

Country Status (7)

Country Link
US (1) US8765791B2 (OSRAM)
EP (1) EP2262499B1 (OSRAM)
JP (1) JP5593234B2 (OSRAM)
CN (1) CN102014900B (OSRAM)
AU (1) AU2009225189B2 (OSRAM)
CA (1) CA2717904C (OSRAM)
WO (1) WO2009111868A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2639757T3 (es) 2010-04-06 2017-10-30 University Health Network Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales
WO2013101617A1 (en) * 2011-12-29 2013-07-04 Purdue Research Foundation Method for assessing a liver of a patient having a chronic hepatitis b virus infection
MX357763B (es) 2013-10-18 2018-07-23 Univ Health Network Tratamiento para cancer pancreatico.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370168A (zh) * 1999-08-20 2002-09-18 万有制药株式会社 新的螺环化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016921B (en) * 1978-03-27 1982-08-18 Taiho Pharmaceutical Co Ltd Anti cancer compositions containing uracil derivatives
AU2001264376A1 (en) * 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
JP3876254B2 (ja) 2001-09-04 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2492225A1 (en) * 2002-07-18 2004-01-29 Merck & Co., Inc. Combination therapy for the treatment of obesity
WO2004110375A2 (en) * 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US20050288279A1 (en) * 2004-06-24 2005-12-29 Rozman Karl K Phenothiazine derivatives and their method of use
EP1968979A2 (en) * 2005-12-08 2008-09-17 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370168A (zh) * 1999-08-20 2002-09-18 万有制药株式会社 新的螺环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Massimiliano Ruscica et aL.Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer.《PEPTIDES》.2007,第28卷(第2期),426-434. *

Also Published As

Publication number Publication date
AU2009225189B2 (en) 2012-08-02
WO2009111868A1 (en) 2009-09-17
US8765791B2 (en) 2014-07-01
CA2717904C (en) 2016-08-30
US20110112102A1 (en) 2011-05-12
EP2262499A4 (en) 2012-03-21
JP5593234B2 (ja) 2014-09-17
EP2262499B1 (en) 2016-12-21
CN102014900A (zh) 2011-04-13
JP2011513438A (ja) 2011-04-28
EP2262499A1 (en) 2010-12-22
CA2717904A1 (en) 2009-09-17
AU2009225189A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
CN100581585C (zh) 癌症治疗药
JP5563950B2 (ja) 組合せ療法
CN102014900B (zh) 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
CN111344013A (zh) Nox抑制剂用于治疗癌症的用途
US20090203718A1 (en) Cancer treatment method
US12195468B2 (en) TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof
US11492362B1 (en) Pyridine derivatives for the treatment of hyperproliferative diseases
HK1152248A (en) Mk-0557 for use in the treatment of cancer
HK1152248B (en) Mk-0557 for use in the treatment of cancer
HK40113079A (en) Antineoplastic combinations of neratinib and capecitabine
JP2024506314A (ja) がん治療のための併用療法
CN120936376A (zh) 用于治疗与etbr激活相关的癌症的方法
ZA200506211B (en) Combination therapy of ZD6474 with 5-FU or/and CT-11
US20120035183A1 (en) Cancer Treatment Method
HK1239521A1 (en) Antineoplastic combinations of neratinib and capecitabine
HK1239521B (en) Antineoplastic combinations of neratinib and capecitabine
HK1228780A1 (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
HK1158077A (en) Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140402

Termination date: 20180310

CF01 Termination of patent right due to non-payment of annual fee